# Ipamorelin Dosage: What the Studies Administered (Research Context)

> Ipamorelin dosage in the research literature — the doses, routes, half-life, and reconstitution context actually studied, in third person. No human dosing recommendations.

What was administered, to which species, by which route, and how fast it clears. A research-context record, with no human dosing advice.

## Read this first

This page reports ipamorelin dosage the way the studies report it — what was given, to which animal or which volunteers, by which route — and nothing more. There is no recommended human dose here, because none exists: ipamorelin is not an approved medicine, and the popular subcutaneous routines people use have never been tested for dose or safety in a published human study [15]. The numbers below are research figures. The human data come from just two studies — a pharmacokinetic study that mapped how the peptide clears [2] and a Phase 2 trial that used a fixed weight-based IV dose [3]. Everything else is from rats and other animals. The clearest fact a reader can take away is the timing: in people, ipamorelin clears with a half-life of about 2 hours and produces a single GH pulse roughly 40 minutes after a dose [2]. Treat the rest as 'this is what was studied,' never 'this is what to take.'

## The doses actually studied

Across the published record, the doses administered were:

- **Human PK/PD study:** 4.21–140.45 nmol/kg IV over 15 minutes, as single doses, in healthy male volunteers [2].
- **Human Phase 2 ileus RCT:** 0.03 mg/kg IV twice daily for up to 7 days in bowel-resection patients [3].
- **Rat bone-growth study:** 18, 90, and 450 µg/day subcutaneously, divided three times daily, for 15 days [4].
- **Ferret cachexia study (2024):** 1–3 mg/kg intraperitoneally [5].
- **Rat glucocorticoid study:** ipamorelin 0.4–1.6 mg/kg/day IV (four times daily), alongside methylprednisolone [14].

These are dosing facts from animal and early-human research, reported in third person. They are not a schedule for anyone.

## Half-life, clearance, and the routes studied

In healthy human volunteers, ipamorelin's terminal half-life is approximately 2 hours (IV), with clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg; the GH response is a single discrete pulse peaking around 40 minutes (0.67 h) after dosing [2]. In rats, plasma clearance is roughly 5-fold lower than GHRP-6, with 60–80% of the dose recovered intact in bile and urine and intranasal bioavailability around 20% [12].

The routes that appear in the literature are intravenous (human PK and the clinical trial; rodent efficacy), subcutaneous (rodent bone and body-composition work, and the dominant route in community use), intranasal (rodent PK, ~20% bioavailability), and intraperitoneal (rodent and ferret efficacy). Ipamorelin itself is not orally bioavailable; only engineered ipamorelin-derived analogs show meaningful oral absorption.

## How much cjc-1295 ipamorelin should i take?

There is no answer to 'how much cjc-1295 ipamorelin should i take' that can be drawn from controlled human evidence, because no published human trial has dosed the combination for any outcome — the safe, accurate reply is that no validated human dose exists. The single-agent human data that does exist is a pharmacokinetic study using IV infusions of 4.21–140.45 nmol/kg [2] and a Phase 2 trial using 0.03 mg/kg IV [3]; neither establishes a self-administration dose, and community subcutaneous routines have no peer-reviewed basis. This site reports studied doses in third person and recommends none.

## How to reconstitute cjc-1295 ipamorelin 5mg?

Questions about how to reconstitute cjc-1295 ipamorelin 5mg point to general peptide-handling, not a clinical procedure, and this site describes only what the research-supply literature notes. Ipamorelin is supplied as a lyophilized (freeze-dried) powder — free base or acetate salt — and is reconstituted with bacteriostatic water for research handling. As a peptide it degrades with heat and repeated freeze-thaw, so reconstituted solution is typically kept refrigerated. These are general handling observations, not a preparation instruction, and there is no validated human-use protocol for the combination.

## Why dosing precision is limited here

Human evidence for ipamorelin is limited and largely negative for the indication tested. One Phase 2 RCT (n=114) missed its primary endpoint [3]; one PK/PD study (n=8/dose) characterized the ~2-hour half-life [2]. There are no completed Phase 3 trials and no approved indication, so there is no labeled dose to quote. Most human use is off-label and self-administered without controlled-trial support, and a 2026 review explicitly flags the absence of validated efficacy-monitoring and safety frameworks for peptides in this class [15]. That gap is exactly why this page stays in the third person.

---

An optimistic, plain-English ordering of the ipamorelin record — the selective GH pulse logged where the studies confirm it, the cortisol and prolactin pathways left dark, the lone failed human trial kept in full view, and the community reports walled off as anecdote; a reading console pointed at the science, never a clinic, and nothing here dosed, prescribed, or sold.